Article
Version 1
Preserved in Portico This version is not peer-reviewed
VIGI-4: Development of a Novel Pharmacovigilance Method Using ChatGPT
Version 1
: Received: 6 April 2024 / Approved: 8 April 2024 / Online: 8 April 2024 (11:16:12 CEST)
How to cite: Teperikidis, E.; Papazisis, G. VIGI-4: Development of a Novel Pharmacovigilance Method Using ChatGPT. Preprints 2024, 2024040523. https://doi.org/10.20944/preprints202404.0523.v1 Teperikidis, E.; Papazisis, G. VIGI-4: Development of a Novel Pharmacovigilance Method Using ChatGPT. Preprints 2024, 2024040523. https://doi.org/10.20944/preprints202404.0523.v1
Abstract
This study proposes an innovative pharmacovigilance approach, VIGI-4, leveraging ChatGPT Teams Pro version. Our method involves aggregating data from all phase 4 studies published in February 2024 to identify adverse reactions. These results are categorized by disease state alphabetically, demonstrating the method's capacity to generate structured and easily navigable outputs. The results section is tailored to exemplify the valuable, actionable insights attainable through our workflow. This research emphasizes the game-changing potential of integrating advanced technologies such as ChatGPT into pharmacovigilance, signaling a new era in safeguarding drug safety.
Keywords
pharmacovigilance; adverse drug reactions; ChatGPT; artificial intelligence; phase 4 studies; drug safety
Subject
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment